News | Sirnaomics

Press Release

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

2022.08.29

Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

2022.08.26

Sirnaomics' 2022 interim results presentation will be held on 31 August 2022

2022.08.23

Sirnaomics in the News

Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year

2022-08

Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases

2022-08

After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology

2022-02

Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public

2021-07

RNA Silencing Finds Its Therapeutic Voice

2020-03

Hunt for New Coronavirus Treatments Includes Gene-Silencing And Monoclonal Antibodies

2020-02

Coronavirus: AbbVie and Sirnaomics Drug Candidates Explored

2020-01

Sirnaomics to Develop RNAi-based Therapeutics for 2019-nCoV Infections

2020-01

Media Outreach

Sirnaomics Ltd.

401 Professional Dr, STE 280，Gaithersburg, MD 20879, USA

Telephone: +1 301-740-1730